- Home
- GMAB vs BEKE Comparison
GMAB vs BEKE Comparison
Compare GMAB & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BEKE
- Stock Information
- Founded
- GMAB 1999
- BEKE 2001
- Country
- GMAB Denmark
- BEKE China
- Employees
- GMAB N/A
- BEKE N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BEKE Real Estate
- Sector
- GMAB Health Care
- BEKE Finance
- Exchange
- GMAB Nasdaq
- BEKE Nasdaq
- Market Cap
- GMAB 17.4B
- BEKE 18.8B
- IPO Year
- GMAB N/A
- BEKE 2020
- Fundamental
- Price
- GMAB $30.42
- BEKE $16.86
- Analyst Decision
- GMAB Strong Buy
- BEKE Strong Buy
- Analyst Count
- GMAB 6
- BEKE 5
- Target Price
- GMAB $40.40
- BEKE $24.36
- AVG Volume (30 Days)
- GMAB 2.4M
- BEKE 5.2M
- Earning Date
- GMAB 11-06-2025
- BEKE 11-10-2025
- Dividend Yield
- GMAB N/A
- BEKE 2.14%
- EPS Growth
- GMAB 132.41
- BEKE N/A
- EPS
- GMAB 25.10
- BEKE 0.42
- Revenue
- GMAB $3,845,670,022.00
- BEKE $14,540,474,652.00
- Revenue This Year
- GMAB $24.92
- BEKE $12.62
- Revenue Next Year
- GMAB $15.97
- BEKE $12.24
- P/E Ratio
- GMAB $11.82
- BEKE $40.38
- Revenue Growth
- GMAB 29.57
- BEKE 25.42
- 52 Week Low
- GMAB $17.24
- BEKE $15.39
- 52 Week High
- GMAB $33.65
- BEKE $25.17
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- BEKE 44.05
- Support Level
- GMAB $28.08
- BEKE $15.39
- Resistance Level
- GMAB $30.78
- BEKE $17.23
- Average True Range (ATR)
- GMAB 0.68
- BEKE 0.47
- MACD
- GMAB 0.10
- BEKE 0.04
- Stochastic Oscillator
- GMAB 84.63
- BEKE 54.61
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BEKE KE Holdings Inc (each representing three)
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.